You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Glaxosmithkline Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Glaxosmithkline
International Patents:716
US Patents:32
Tradenames:104
Ingredients:90
NDAs:149
Drug Master File Entries: 8
PTAB Cases with Glaxosmithkline as petitioner: See PTAB cases with Glaxosmithkline as petitioner

Drugs and US Patents for Glaxosmithkline

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Glaxosmithkline ANTEPAR piperazine citrate TABLET;ORAL 009102-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe
Glaxosmithkline BACTOCILL oxacillin sodium INJECTABLE;INJECTION 061334-007 Mar 26, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe
Glaxosmithkline EPIVIR-HBV lamivudine TABLET;ORAL 021003-001 Dec 8, 1998 DISCN Yes No ⤷  Subscribe ⤷  Subscribe
Glaxosmithkline MONOCID cefonicid sodium INJECTABLE;INJECTION 050579-001 May 23, 1984 DISCN No No ⤷  Subscribe ⤷  Subscribe
Glaxosmithkline TRELEGY ELLIPTA fluticasone furoate; umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 209482-002 Sep 9, 2020 RX Yes Yes 7,488,827 ⤷  Subscribe Y Y ⤷  Subscribe
Glaxosmithkline WELLBUTRIN bupropion hydrochloride TABLET;ORAL 018644-002 Dec 30, 1985 DISCN Yes No ⤷  Subscribe ⤷  Subscribe
Glaxosmithkline ZEJULA niraparib tosylate TABLET;ORAL 214876-001 Apr 26, 2023 RX Yes No 8,859,562 ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries

Expired US Patents for Glaxosmithkline

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Glaxosmithkline AGENERASE amprenavir CAPSULE;ORAL 021007-002 Apr 15, 1999 5,646,180 ⤷  Subscribe
Glaxosmithkline Llc DYNACIRC CR isradipine TABLET, EXTENDED RELEASE;ORAL 020336-001 Jun 1, 1994 4,950,486 ⤷  Subscribe
Glaxosmithkline Llc DYNACIRC CR isradipine TABLET, EXTENDED RELEASE;ORAL 020336-001 Jun 1, 1994 4,946,687 ⤷  Subscribe
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-001 Jun 1, 1995 6,020,001*PED ⤷  Subscribe
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-001 Aug 26, 1997 5,307,953*PED ⤷  Subscribe
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-003 Sep 4, 2003 5,681,588 ⤷  Subscribe
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 5,403,830 ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 7 of 7 entries
Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 3 mg, 4 mg and 5 mg ➤ Subscribe 2005-02-04
➤ Subscribe Tablets 250 mg/100 mg ➤ Subscribe 2009-04-03
➤ Subscribe Extended-release Capsules 325 mg ➤ Subscribe 2006-11-07
➤ Subscribe Oral Suspension 750 mg/5 mL ➤ Subscribe 2009-10-20
➤ Subscribe Extended-release Tablets 4 mg ➤ Subscribe 2008-10-31
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe 2009-01-08
➤ Subscribe Extended-release Tablets 2 mg ➤ Subscribe 2008-10-14
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe 2009-01-08
➤ Subscribe Injection 6 mg/0.5 mL, 0.5 mL vials ➤ Subscribe 2004-10-25
➤ Subscribe Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2004-12-22
➤ Subscribe Tablets 100 mg ➤ Subscribe 2007-10-31
➤ Subscribe Tablets 62.5 mg/25 mg ➤ Subscribe 2010-09-14
➤ Subscribe Extended-release Capsules 225 mg and 425 mg ➤ Subscribe 2006-10-11
➤ Subscribe Extended-release Tablets 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg ➤ Subscribe 2014-02-12
➤ Subscribe Extended-release Tablets 8 mg ➤ Subscribe 2008-11-03
➤ Subscribe Extended-release Tablets 12 mg ➤ Subscribe 2009-02-05
➤ Subscribe Extended-release Tablets 6 mg ➤ Subscribe 2009-07-22
➤ Subscribe Tablets 150 mg ➤ Subscribe 2007-10-30
➤ Subscribe Orally Disintegrating Tablets 25 mg, 50 mg, 100 mg, and 200 mg ➤ Subscribe 2009-12-21
➤ Subscribe Injection 6 mg/0.5 mL, 0.5 mL (prefilled syringes) ➤ Subscribe 2006-05-09

International Patents for Glaxosmithkline Drugs

CountryPatent NumberEstimated Expiration
Argentina 050902 ⤷  Subscribe
Canada 2647545 ⤷  Subscribe
China 101505752 ⤷  Subscribe
Japan 2005515039 ⤷  Subscribe
Poland 370276 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2004011069 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2018183354 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration
Showing 1 to 7 of 7 entries

Supplementary Protection Certificates for Glaxosmithkline Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
1633724 122015000025 Germany ⤷  Subscribe PRODUCT NAME: OLAPARIB, SOWIE SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
1740177 300694 Netherlands ⤷  Subscribe PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430
2109608 326 50007-2018 Slovakia ⤷  Subscribe PRODUCT NAME: NIRAPARIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1235/001 - EU/1/17/1235/003 20171120
1740177 58/2014 Austria ⤷  Subscribe PRODUCT NAME: UMECLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922 (MITTEILUNG) 20140430
1633724 C20150012 00136 Estonia ⤷  Subscribe PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
2316456 LUC00054 Luxembourg ⤷  Subscribe PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
2109608 SPC/GB18/016 United Kingdom ⤷  Subscribe PRODUCT NAME: NIRAPARIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PARTICULARLY THE TOSYLATE OR A HYDRATE, ESPECIALLY THE TOSYLATE MONOHYDRATE; REGISTERED: UK EU/1/17/1235 20171120; UK PLGB 19494/0294 20171120
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 7 of 7 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.